Determination of the Efficiency of 8 mg Doxazosin XL Treatment in Patients With an Inadequate Response to 4 mg Doxazosin XL Treatment for Benign Prostatic Hyperplasia

Keten, Tanju; Aslan, Yılmaz; Balcı, Melih; Tuncel, Altuğ; Bilgin, Ovunc; Dilmen, Cem; Özdemir, Ümit; Yahşi, Sedat; Güzel, Özer; Atan, Ali

doi:10.1016/j.urology.2014.10.004

Cited by 5 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The included RCTs comprised the currently used six kinds of α-blockers with different dose categories including Naftopidil 25 mg, 50 mg and 75 mg, Silodosin 8 mg, Tamsulosin 0.2 mg and 0.4 mg, Alfuzosin 2.5 mg and 10 mg, Doxazosin 2 mg, 4 mg and 8 mg, Terazosin 0.5 mg with a total 3,371 participants. Among the 22 included studies, 10 were multi-centric 26 , 29 , 31 , 32 , 34 , 36 , 39 – 42 , while 12 were single-centric 12 – 14 , 27 , 28 , 30 , 33 , 35 , 37 , 38 , 43 , 44 . Nine trials were conducted in Japan 26 , 30 – 33 , 36 , 39 , 40 , 43 , five in India 12 – 14 , 37 , 44 , two in Korea 41 , 42 and one each in China 34 , Indonesia 29 , Europe 27 , Philippines 28 , Egypt 35 and Turkey 38 .…”

Section: Resultsmentioning

confidence: 99%

“…Among the 22 included studies, 10 were multi-centric 26 , 29 , 31 , 32 , 34 , 36 , 39 – 42 , while 12 were single-centric 12 – 14 , 27 , 28 , 30 , 33 , 35 , 37 , 38 , 43 , 44 . Nine trials were conducted in Japan 26 , 30 – 33 , 36 , 39 , 40 , 43 , five in India 12 – 14 , 37 , 44 , two in Korea 41 , 42 and one each in China 34 , Indonesia 29 , Europe 27 , Philippines 28 , Egypt 35 and Turkey 38 . Most studies (91%) were published after 2005 and, over half of the studies (50%) involved more than 100 patients.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Comparative efficacy and safety of alpha-blockers as monotherapy for benign prostatic hyperplasia: a systematic review and network meta-analysis

Yoosuf,

Panda,

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Despite the availability of various drugs for benign prostatic hyperplasia (BPH), alpha(α)-blockers are the preferred first-line treatment. However, there remains a scarcity of direct comparisons among various α-blockers. Therefore, this network meta-analysis (NMA) of randomized controlled trials (RCTs) aimed to evaluate the efficacy and safety of α-blockers in the management of BPH. A comprehensive electronic search covered PubMed, Embase, Ovid MEDLINE, and Cochrane Library until August 2023. The primary endpoints comprised international prostate symptom score (IPSS), maximum flow rate (Qmax), quality of life (QoL), and post-void residual volume (PVR), while treatment-emergent adverse events (TEAEs) were considered as secondary endpoints. This NMA synthesized evidence from 22 studies covering 3371 patients with six kinds of α-blockers with 12 dose categories. IPSS has been considerably improved by tamsulosin 0.4 mg, naftopidil 50 mg and silodosin 8 mg as compared to the placebo. Based on the p-score, tamsulosin 0.4 mg had the highest probability of ranking for IPSS, PVR, and Qmax, whereas doxazosin 8 mg had the highest probability of improving QoL. A total of 297 adverse events were reported among all the α-blockers, silodosin has reported a notable number of TEAEs. Current evidence supports α-blockers are effective in IPSS reduction and are considered safer. Larger sample size with long-term studies are needed to refine estimates of IPSS, QoL, PVR, and Qmax outcomes in α-blocker users.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Comparative efficacy and safety of alpha-blockers as monotherapy for benign prostatic hyperplasia: a systematic review and network meta-analysis

Yoosuf,

Panda,

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Keten et al. 37 reported that treatment of 8 mg doxazosin XL is an effective choice for patients who do not respond to treatment with 4 mg doxazosin XL with no changes in side effects. In our study, only the study that evaluated the effect of doxazosin 4 mg group was included, so further evaluation is required for the effect of doxazosin.…”

Section: Discussionmentioning

confidence: 99%

Comparing effects of alpha-blocker management on acute urinary retention secondary to benign prostatic hyperplasia: A systematic review and network meta-analysis

Gwon¹,

Park²,

Yang³

et al. 2023

Prostate International

View full text Add to dashboard Cite

“…La investigación de Keten y su equipo de trabajo, en la que evaluaron las dosis de 4 mg/día versus 8 mg/día de doxazosina, reportó eficacia similar con ambos protocolos para el tratamiento los síntomas urinarios de la vía baja; la dosis de 8 mg/día fue una elección eficaz para los pacientes con reacción inadecuada a la dosis de 4 mg/día. 12…”

Section: Doxazosinaunclassified

Tratamiento farmacológico de la hiperplasia prostática benigna. Revisión de la bibliografía

Medina-Rico

López-Ramos

Bastidas

et al. 2018

rmu

View full text Add to dashboard Cite

La hiperplasia prostática benigna afecta a 50% de la población mundial, principalmente a pacientes de 70-80 años de edad. Actualmente existen diferentes tratamientos, pero el farmacológico se considera el de primera línea. El objetivo de esta revisión fue encontrar la bibliografía relacionada con el tratamiento farmacológico de la hiperplasia prostática benigna. Para la investigación se revisaron las bases de datos y repositorios: Medline, Embase, Central, Scopus y LILACS. Solo se incluyeron estudios clínicos que evaluaron la eficacia de los diferentes fármacos indicados a pacientes con hiperplasia prostática benigna. Se registraron 1595 referencias revisadas por título y resumen, pero solo se seleccionaron 49 para la revisión de texto completo. Los medicamentos identificados fueron: tamsulosina, alfusosina, doxazosina, silodosina, dutasterida, finasterida, fesoterodina tadalafilo, sildenafilo y naftopidilo. Además, se encontraron estudios de fitoterapia que evaluaron la eficacia de Serenoa repens. La mayor parte de los medicamentos son efectivos para el tratamiento de los síntomas urinarios provocados por la hiperplasia prostática benigna. Los resultados coinciden con las recomendaciones de las últimas guías de práctica clínica. La elección del medicamento de primera línea depende del médico tratante, quien debe considerar, principalmente, los posibles eventos adversos y las preferencias del paciente. PALABRAS CLAVE: Hiperplasia prostática benigna; tratamiento farmacológico; fitoterapia, síntomas de la vía urinaria baja.

show abstract

Determination of the Efficiency of 8 mg Doxazosin XL Treatment in Patients With an Inadequate Response to 4 mg Doxazosin XL Treatment for Benign Prostatic Hyperplasia

Cited by 5 publications

References 9 publications

Comparative efficacy and safety of alpha-blockers as monotherapy for benign prostatic hyperplasia: a systematic review and network meta-analysis

Comparative efficacy and safety of alpha-blockers as monotherapy for benign prostatic hyperplasia: a systematic review and network meta-analysis

Comparing effects of alpha-blocker management on acute urinary retention secondary to benign prostatic hyperplasia: A systematic review and network meta-analysis

Tratamiento farmacológico de la hiperplasia prostática benigna. Revisión de la bibliografía

Contact Info

Product

Resources

About